Glucagon-like peptide-1 receptor (GLP-1) agonists, widely used to treat obesity and diabetes, may also improve key outcomes for patients with Crohns disease, according to a large real-world study presented during the 2026 Crohns & Colitis Congress, a partnership of AGA and the Crohn's & Colitis Foundation, taking place in Las Vegas
You can learn more about how compounded semaglutide works here
Combining HQ with a steroid cream and tretinoin have superior efficacy when compared to HQ alone
GLP-1(736) and exenatide activated GLP-1Rs expressed on microglial cells in the spinal dorsal horn, which were significantly upregulated following peripheral nerve injury
Here are some of the best options from mCaffeine that support healthy, nourished skin
Using IV therapy can drive greater transport of these key mood regulating substances into the brain